INSIGHTS ON CLINICAL TRIAL PARTNERING

• Podcast―Nonclinical Considerations When Developing Ophthalmic Drugs

  Globally recognized consultants discuss how they are addressing the most pressing drug development topics in the ocular field.

• Do CROs Need To Reinvent Themselves In 2025?

  Facing economic pressures, regulatory changes, and technological advancements, CROs must redefine their value propositions and discuss the need for reinvention in 2025 to accelerate into the future.

• At-Home Clinical Trials: When At-Home Ophthalmic Exams Make Sense

  At-home ophthalmic exams in clinical trials improve patient accessibility, reduce site burden, and maintain data integrity, enabling decentralized research without sacrificing quality or compliance.

• Decentralized Trials Still Need Connected Support

  Decentralized and hybrid trials reduce travel burdens but add coordination challenges. Strong support improves communication, engagement, and smooth trial execution from enrollment to completion.

• Bringing Clinical Trials To Everyone's Backyard

  1/10/2025

  Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.

• 5 Proven Ways To Expand Clinical Trial Site Capacity

  9/18/2025

  How can you turn capacity limits into enrollment momentum and ensure timelines stay on track while also expanding access to diverse patient populations?

• How A Biotech Startup Transformed Its Clinical Trial Supply Management

  2/25/2026

  Don’t let your trial get lost in the shuffle of legacy vendors. See how a high-touch, consultative approach can protect your study’s future.

• Improving Trial Readiness Through Community‑Based Models

  5/19/2026

  This webinar explores how inclusive research can be advanced through community partnership models that improve access, build trust and support stronger enrollment and retention. 

• Breaking Silos In Drug Development: The Power Of An Integrated Model

  5/11/2026

  Experts share how Altasciences' integrated Preclinical/Clinical model results in fewer handoffs, greater continuity, and accelerated progress from the nonclinical phase to first-in-human trials.